Biosimilars: Another psoriatic disease treatment option?

| Tamara Miller
Food and Drug Administration approval of a biosimilar drug for cancer in March signals the arrival of a new class of treatment options for people battling serious and chronic illnesses like psoriasis and psoriatic arthritis. 
But FDA approval of biosimilar drugs – drugs that are similar, but not exact replicas of biologics – also raises questions and concerns--how effective and safe will biosimilars be? Will they be more affordable than biologic drugs? Will doctors or insurance companies have final say on substituting a biosimilar for a biologic drug?
The issue of biosimilars is as complicated as the drugs they aim to mimic. Biologic drugs are derived from living human cells cultured in a laboratory. They are given by injection or infusion, and treat psoriasis and psoriatic arthritis by targeting specific parts of the immune system that cause the psoriatic inflammation. Because of the complexity, it’s not possible for a biosimilar to be an exact copy of a biologic. 
In other words, that Remicade biosimilar the FDA is slated to review soon may be similar to Remicade, but it is by no means a generic version of the drug. 
As a patient advocacy organization, the National Psoriasis Foundation supports the development of safe and effective treatment options, but emphasizes that the doctor-patient relationship should be at the core of all treatment decisions. 
We recently invited Dr. Craig Leonardi, a dermatologist at Central Dermatology in St. Louis and a clinical assistant professor at St. Louis University, to answer patient-submitted questions about biosimilars for one of our free webcasts. 
Leonardi explained how biosimilars are tested for safety and efficacy by using the concept of extrapolation: 
Extrapolation is a concept where you might test your biosimilar drug in psoriasis, but then if it was proven to be similar and it was called a biosimilar, then the drug could be prescribed for not only psoriasis but psoriatic arthritis, for rheumatoid arthritis, for other disease states that were originally approved for use when using the reference molecule … A biosimilar etanercept (Enbrel) might be tested in psoriasis, found to be similar, but then it would be given the green light for treating rheumatoid arthritis patients. It’s an unsettling concept for many physicians and perhaps some patients. 
Leonardi also discussed the cost of biosimilars. One viewer asked whether they will really be more affordable than biologics.
We have absolutely no idea … right now, as many of you know, there are generous patient assistance programs made by the manufacturers of the reference compounds. Enbrel and Humira, frequently patients get that for $5 a month. That price is achieved through patient assistance programs.  The AbbVie patient assistance program would never be used to adjust the price of biosimilar Humira. And so something is going to have to happen at the pricing level, at the insurance company level too, to even the playing field, and I frankly have no idea about how that is going to happen. I’m sure it’s going to start out being a bit messy and then it will get cleaned up.  
Listen to the full Q&A with Leonardi, as well as view his in-depth explanation of biosimilars below. 

Several states across the country are considering legislation that will determine how biosimilars are prescribed and who—doctors or insurance companies—gets to decide when a biosimilar is substituted for a biologic. You can get involved in our efforts to support legislation that puts the doctor and patient relationship first by emailing [email protected]

Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Blog Posts

A veteran volunteer recalls her rookie experience with patient advocacy and...
collage of medical symbols
As states battle to shore up their health insurance exchanges, some are taking...
Volunteer advocates pose with Assemblywoman Cecilia Aguiar-Curry
Telling our stories and making connections at the 2018 California Advocacy...
Patient advocates at California Advocacy Summit April 16 2018
Controlling out-of-pocket costs – our top priority – gains more followers.
Patient advocates visiting Congress
On Capitol Hill Day, we asked lawmakers for more funding for research and less...
You may not be able to attend our biggest advocacy event of the year, but you...
Are you a science buff or a research novice? Test your knowledge with this five...
Join us as we meet with Minnesota lawmakers in our fight against step therapy.
You can join the fight to stop step therapy.